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Background: Klebsiella pneumoniae outbreaks possessing extended-spectrum β-lactamase- (ESBL) mediated
resistance to third-generation cephalosporins have increased significantly in hospital and community settings
worldwide. The study objective was to characterize prevalent genetic determinants of TEM, SHV and CTX-M types
ESBL activity in K. pneumoniae isolates from Egypt.
Methods: Sixty five ESBL-producing K. pneumoniae strains, isolated from nosocomial and community-acquired
infections from 10 Egyptian University hospitals (2000–2003), were confirmed with double disc-synergy method and
E-test. blaTEM, blaSHV and blaCTX-m genes were identified by PCR and DNA sequencing. Pulsed-field gel
electrophoresis (PFGE) was conducted for genotyping.
Results: All isolates displayed ceftazidime and cefotaxime resistance. blaTEM and blaSHV genes were detected in
98% of the isolates’ genomes, while 11% carried blaCTX-m. DNA sequencing revealed plasmid-borne SHV-12,-5,-2a
(17%), CTX-m-15 (11%), and TEM-1 (10%) prevalence. Among SHV-12 (n=8), one isolate displayed 100% blaSHV-12
amino acid identity, while others had various point mutations: T17G (Leu to Arg, position 6 of the enzyme: n=2);
A8T and A10G (Tyr and Ile to Phe and Val, positions 3 and 4, respectively: n=4), and; A703G (Lys to Glu 235: n=1).
SHV-5 and SHV-2a variants were identified in three isolates: T17G (n=1); A703G and G705A (Ser and Lys to Gly and
Glu: n=1); multiple mutations at A8T, A10G, T17G, A703G and G705A (n=1). Remarkably, 57% of community-acquired
isolates carried CTX-m-15. PFGE demonstrated four distinct genetic clusters, grouping strains of different genetic
backgrounds.
Conclusions: This is the first study demonstrating the occurrence of SHV-12, SHV-5 and SHV-2a variants in Egypt,
indicating the spread of class A ESBL in K. pneumoniae through different mechanisms.Background
K. pneumoniae is a facultative anaerobic, Gram negative
bacteria of the Enterobacteriaceae family, and a reported
opportunistic pathogen that has been implicated in
many community- and hospital-acquired infections [1].
This organism can initiate urinary tract infections, wound
infections, pneumonia, intra-abdominal infections, nasal
mucosa atrophy, and rhinoscleroma. The number of out-
breaks involving K. pneumoniae strains with extended
spectrum β-lactamase (ESBL) mediated resistance to* Correspondence: enasnewire@hotmail.com
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reproduction in any medium, provided the orthird-generation cephalosporins has been progressively
increasing in many parts of the world [1].
β-lactamases, the precursors to ESBLs, confer resist-
ance by inactivating β-lactam antibiotics [2], like penicil-
lins, cephalosporins, carbapenems, and monobactams,
by breaking open the four atom β-lactam ring structure.
The extended spectrum β-lactamases (ESBLs) are a rapidly
developing group of enzymes with the ability to hydrolyze
third-generation cephalosporins as well as the mono-
bactams and aztreonams that are known to be active
against Klebsiella species. Clavulanic acid is a potent in-
hibitor of the β-lactamases and is commonly included with
β-lactam antibiotics when an ESBL-producing bacterium
is suspected. Clavulanic acid is a member of the clavams
or oxapenams that inhibits β-lactamase activity by cova-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the enzyme.
ESBL genes originally evolved from the β-lactamase
TEM-1, TEM-2, and SHV-1 genes through mutations of
the amino acids surrounding the active site β-lactamases.
ESBLs have recently become a significant problem
because they are commonly plasmid-encoded, facilitat-
ing a high rate of horizontal transfer between different
bacterial species [3]. Furthermore, such plasmids typic-
ally carry resistance genes to other drugs such as the
aminoglycosides, thus narrowing treatment options.
As an illustration, administration of cephalosporins has
recently been linked to increasing treatment failure rates,
and isolated strains have been found to possess higher
minimal inhibitory concentration (MIC) rates for ceftriax-
one, cefotaxime and, to a lesser extent, ceftazidime.
However, this resistance diminishes in the presence of
β-lactamase inhibitors, such as clavulanic acid [4]. This
type is considered class-A ESBL resistance, where the
TEM, SHV and CTX-M type ESBL enzymes are able to
hydrolyze [5].
Previous molecular characterization studies on TEM,
SHV, and CTX-m genes and their derivatives, e.g.
blaTEM-1 and blaSHV-12, have shown that they are ep-
idemiologically related, and are both plasmid-borne [6].
PFGE have also been widely employed to investigate
the epidemiological and genotypic relatedness of ESBL-
producing bacteria [1] and to track evolving strains
implicated in various geographic regions [6]. Recent
studies in the Middle East have revealed a high prevalence
of ESBL-producing K. pneumoniae isolates in Israel [7],
and extensive spread of those carrying CTX-m-15 was
reported in Lebanon, Kuwait, and Egypt [8-10]. In Saudi
Arabia, CTX-M-15 producing K. pneumoniae was respon-
sible for a neonatal intensive care unit outbreak [11].
Our goal was to characterize and determine the preva-
lence of genetic elements of ESBL-producingK. pneumoniae
collected between 2000 and 2003 in Egypt. Isolates in
this study including those from both community-acquired
and nosocomial infections, were genotyped and their
DNA fingerprints were compared.
Methods
Bacterial isolates
A total of 65 K. pneumoniae were isolated from blood
specimens collected as part of an infection control surveil-
lance study carried out by the Infection Control Unit,
Global Disease Detection and Response Program (GDDRP),
U.S. NavalMedical Research Unit No. 3 (NAMRU-3), Cairo,
Egypt, in partnership with the U.S. Centers for Disease
Control and Prevention (CDC) (Table 1). Isolates were
collected from 10 different Egyptian teaching hospitals
distributed across seven governorates in Egypt: Cairo,
Alexandria, Suez, Sohag, Dakahlia, Sharkiya, and KafrEl-Sheikh. Microbiological isolation and biochemical
identification procedures were conducted according to
Clinical and Laboratory Standards Institute procedures
(CLSI) [12].
Antibiotic susceptibility testing and ESBL detection
Antibiotic susceptibility was determined by the agar disk
diffusion method. The following antibiotics were tested:
ampicillin (30 μg), imipenem (10 μg), cefepime (30 μg),
cephalothin (30 μg), ceftriaxone (30 μg), cefpodoxime
(10 μg), ceftazidime (30 μg), cefotaxime (30 μg), and sulfa-
methoxazole (30 μg) (Becton Dickinson, Sparks, MD,
USA), with results interpreted using the CLSI criteria [12].
Also, minimum inhibitory concentration (MIC) was evalu-
ated by E-test for ceftazidime, cefepime, ceftriaxone, and
cephalothin (bioMérieux, France) [13]. Additionally, the
detection of ESBL activity was screened by double-synergy
test [14]. K. pneumoniae ATCC 700603 and E. coli ATCC
25922 were used as positive and negative controls,
respectively, as recommended by CLSI guidelines for
Enterobacteriaceae [12].
Pulsed-field gel electrophoresis (PFGE)
K. pneumoniae isolates were subjected to PFGE. Total
DNA was extracted and digested using the Xba1restriction
enzyme following the procedures described in the PulseNet
International protocols for Salmonella with minor modifi-
cations pertaining to electrophoresis running conditions in
the CHEF-DR III PFGE system (BioRad, Hercules, USA):
19 hrs, with initial switch time 2.2 sec, final switch time 63.8
sec, at 6 volts, and at 120˚Angle [15].
DNA extraction (chromosomal and plasmid)
Twenty-four hour culture of K.pneumoniae isolates grown
on MacConkey Agar were used for DNA extraction.
Chromosomal and plasmid DNA extractions were per-
formed using the Qiagen Blood Mini Kit (QIAgen Inc.,
Valencia CA, USA), and Wizard plus Minipreps SV DNA
purification system (Promega, Madison, USA), respect-
ively, according to the manufacturer’s instructions. The
quality of the extracted chromosomal and plasmid DNA
was confirmed by running the extracts on 0.8% agarose
gel (100 Volts, 400 amps, for 2 hrs), and by measuring the
concentration of DNA by NanoDrop (Thermo Scientific,
Kansas, USA).
PCR screening for ESBL genes
Both chromosomal and plasmid DNA extracts of all
isolates were screened by PCR for the presence of three
ESBL genes: TEM, SHV, and CTXm. Three sets of primers
were designed for screening (Table 2): a core set to amplify
the conserved, central region of each gene for an initial
screening [16]; two sets of degenerate primers to detect
the more variable upstream and downstream regions of



















1 00-008416 Cairo Univ + Community - - - - + +
2 01-001425 Cairo Univ + Community - - - - + +
3 01-007549 Cairo Univ + Nosocomial - - - - + +
4 01-007550 Cairo Univ + Nosocomial - - - - + +
5 01-007724 Cairo Univ + Nosocomial - + + - + +
6 01-007732 Cairo Univ + Nosocomial - - - - + +
7 01-007743 Cairo Univ + Nosocomial - + + - + +
8 01-007949 Cairo Univ + Nosocomial - - - - + +
9 01-007951 Cairo Univ + Nosocomial - + + - + +
10 01-007953 Cairo Univ + Nosocomial - - - - + +
11 01-007959 Cairo Univ + Nosocomial - + - - + +
12 01-007961 Cairo Univ + Nosocomial - - - - + +
13 01-007967 Cairo Univ + Nosocomial - - - - - -
14 01-008663 Cairo Univ + Nosocomial - - - - + +
15 01-008664 Cairo Univ + Nosocomial - - - - + +
16 01-008666 Cairo Univ + Nosocomial - - + - + +
17 01-008671 Cairo Univ + Nosocomial - - - - + +
18 01-008672 Cairo Univ + Nosocomial - - - - + +
19 01-008884 Cairo Univ + Nosocomial - - - - + +
20 01-009044 Cairo Univ + Nosocomial - - - - + +
21 01-012909 Cairo Univ + Nosocomial - - - - + +
22 01-012910 Cairo Univ + Nosocomial - - - - + +
23 01-012912 Cairo Univ + Nosocomial - - - - + +
24 01-012919 Cairo Univ + Nosocomial - - - - + +
25 01-012921 Cairo Univ + Nosocomial - + - - + +
26 01-012925 Cairo Univ + Nosocomial - - - - + +
27 01-013098 Cairo Univ + Nosocomial - - - - + +
28 01-013099 Cairo Univ + Nosocomial - - - - + +
29 01-013638 Cairo Univ + Nosocomial - - - - + +
30 01-013639 Cairo Univ + Nosocomial - - - - + +
31 01-013640 Cairo Univ + Nosocomial - - - - + +
32 01-013906 Cairo Univ + Nosocomial - - + - + +
33 01-015467 Cairo Univ + Nosocomial - - - - + +
34 01-015468 Cairo Univ + Nosocomial - - - - + +
35 01-015469 Cairo Univ + Nosocomial + - - + + +
36 01-015470 Cairo Univ + Nosocomial + - - + + +
37 01-015472 Cairo Univ + Nosocomial - - - - + +
38 01-015473 Cairo Univ + Nosocomial - - - - + +
39 01-015474 Cairo Univ + Nosocomial - - - - + +
40 01-015475 Cairo Univ + Nosocomial - - - - + +
41 01-015857 Cairo Univ + Nosocomial - - - - + +
42 01-015858 Cairo Univ + Nosocomial - - - - + +
43 01-015859 Cairo Univ + Nosocomial - - - - + +
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Table 1 Strain information (Continued)
44 01-015860 Cairo Univ + Nosocomial - - - - + +
45 01-016401 Cairo Univ + Nosocomial - - + - + +
46 01-017000 Cairo Univ + Nosocomial - - - - + +
47 01-017852 Cairo Univ + Nosocomial - - - - + +
48 01-017853 Cairo Univ + Nosocomial - - - - + +
49 01-017866 Cairo Univ + Nosocomial - - - - + +
50 01-018867 Zagazig Univ + Nosocomial - - + - + +
51 02-000429 Zagazig Univ + Community - - + - + +
52 02-000569 Zagazig General
Hospital
+ Nosocomial - - - - + +
53 02-005285 Mansoura General
Hospital
+ Nosocomial + - - + + +
54 02-005864 Sohag General Hospital + Nosocomial - - - - + +
55 02-009772 Suez General Hospital + Nosocomial - - - - + +
56 02-009785 Sohag General Hospital + Nosocomial - - - - + +
57 02-010707 Fawzi Moaz General
Hospital
+ Nosocomial - - - - + +
58 02-010718 Mansoura General
Hospital
+ Nosocomial - - - - + +
59 02-018404 Suez General Hospital + Nosocomial - - - - + +
60 03-000024 Kafr El Shiek General + Nosocomial - - - - + +
61 03-002582 Kafr El Shiek General
Hospital
+ Nosocomial - - + - + +
62 03-018785 Kafr El Shiek General
Hospital
+ Community + - + + + +
63 03-021318 Kafr El Shiek General
Hospital
+ Community + - - + + +
64 03-021320 Kafr El Shiek General
Hospital
+ Community + - - + + +
65 03-021322 Kafr El Shiek General
Hospital
+ Community + + + + + +
Isolates accessioning numbers utilized in the study are shown above: The first two digits indicate the year of collection. The last six columns indicate the presence
(+) or absence (-) of the genes tested on both chromosomal and plasmid. Community source of infection is distinguished in bold.
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purchased commercially (Sigma-Genosys, Taufkirchen,
Germany). Five μl of the DNA template were added to
complete a final PCR reaction volume of 25 μl containing:
1× green reaction buffer; 3 mM of MgCl2.
(Promega, Madison, USA); 0.3 pM of each primer;
2.5U of GoTaq Flexi DNA Polymerase and 0.4 mM
dNTPs. Template amplification was accomplished using
the following cycle conditions: 95°C for 5 minutes (initial
denaturation),30 cycles of: 94°C for 30 sec (denaturation),
52°C for 45 sec (annealing), and 72°C for 45 sec (exten-
sion), 72°C for 7 min (final extension). The annealing
temperatures and times for TEM, SHV and CTXm were
52°C for 45 sec, 55°C for 1 min, and 57°C for 45 sec,
respectively.
PCR products were visualized on Ethidium-stained 1%
agarose gels with expected product lengths of 643 bp,714 bp and 766 bp for blaTEM, blashv, and blaCTX-m,
respectively.
ESBL gene sequencing
After initial screening for the amplification of core ESBL
genes on both chromosomal and plasmid, the plasmid-
borne TEM, SHV, or CTX-m genes were subjected to
nucleic acid sequencing.
The initial PCR amplified products were purified and
treated with Exo Sap-it enzyme (USB, Santa Clara CA,
USA) at the ratio of 2:1 using 10 μl of the amplicon to 5 μl
of the enzyme. Each mixture was incubated in a conven-
tional thermal cycler (Applied Biosystems, CA, USA) for
15 min at 37°C, followed by 15 min at 80°C according to
the manufacturer’s instructions. Direct sequencing of each
amplicon was carried out using the Sanger dideoxy-
nucleotide chain termination method with the ABI Prism





Core TEM F CAGCGGTAAGATCCTTGAGA 643 [9]
Core TEM R ACTCCCCGTCGTGTAGATAA
Core SHV F GGCCGCGTAGGCATGATAGA 714
Core SHV R CCCGGCGATTTGCTGATTTC
Core CTXM F AACCGTCACGCTGTTGTTAG 766















































Newire et al. Annals of Clinical Microbiology and Antimicrobials 2013, 12:16 Page 5 of 12
http://www.ann-clinmicrob.com/content/12/1/16Big Dye Terminator Cycle Sequencing Reaction Kit
(Applied Biosystems, Inc., Foster City, CA, USA) on an ABI
Prism 3130 Automated Sequencer. Using data collection
software version 2.0, and sequencing analysis software 5.1.1.
For each sequencing reaction, 2 μl purified PCR prod-
uct were added to a final reaction volume of 20 μl
containing 1× of sequencing buffer (Applied Biosystems,
CA, USA); 4 μl BigDye (Applied Biosystems, USA) reac-
tion mix; and 1.5pM of each of the Forward and Reverse
primer. The sequencing cycle was composed of two
stages; stage one is denaturing at 96°C for 10 sec, while
stage two is composed of 25 cycles of denaturing at 96°C
for 10 sec, annealing at 50°C for 5 sec, and extension at
60°C for 4 min.
Each cycle sequence product was purified by spin col-
umn purification according to the manufacturer’s instruc-
tions (Edge Biosystems, CA USA). The purified PCR
product was then completely dried at 85°C for 30–40 min.
Fifteen μl Hi-Di formamide (Applied Biosystems, CA,
USA) was added to the tubes, after which the tubes were
heated for 2 min at 95°C, then immediately placed on ice.Data analyses
Nucleotide sequences obtained from various isolates were
assembled using the software programs BioNumerics (ver-
sion 5.10) and BioEdit (version 7.0.9.0), and aligned with
GenBank reference sequences using the Clustal X applica-
tion within BioEdit. Translated amino acid sequences were
compared with published sequences in the Lahey
organization (http://www.lahey.org/studies). Phylogenetic
tree was generated using the MEGA version 4 software,
and dendrogram were constructed using the neighbor-
joining method [15]. PFGE data from the 65 isolates
was analyzed using BioNumerics (version 5.10). Genetic
similarities were inferred from dendrograms created
using the unweighted pair-group method with average
(UPGMA) analysis of the XbaI mrp–PFGE patterns
using the Dice coefficient with a 1.5% tolerance for the
band migration distance.
Results
Antibiograms of K. pneumoniae isolates
In hospitalized and community cases, 100% of the strains
in this study have shown susceptibility in the presence of
β-lactam inhibitor CAZ/CLA, while 98.5% (64/ 65) were
susceptible to CTX/CLA excluding one isolate (01–
007953) with inhibition zone diameter ≥ 5 mm. Variable
resistance patterns were seen among other antibiotics
(Table 3). All K. pneumoniae isolates displayed resistance
to ampicillin(AM), ceftazidime (CAZ), cephalothin (CE),
ceftriaxone (CF), and cefpodoxime (CPD), while the ma-
jority of isolates, 97%, were resistant to cefotaxime
(CTX). On the other hand, the isolates displayed lower
rates of resistance to sulfamethoxazole (SXT), cefepime
(FEP), (PM), and imipenem (IPM) (49%, 37%, 14%, and
3%, respectively).
Molecular characterization of ESBL genes
Amplification and sequencing primers were designed to
both detect the presence of and generate templates for
the accurate sequencing of the relatively large genes
studied here (Table 2).
Eleven percent of isolates (7/65) carried the CTX-m
gene. The majority (4/7) of the community isolates carried
CTX-m, compared to only 5% (3/58) of the nosocomial
isolates. Amplification of the upstream and downstream
regions and sequencing of the full length PCR products
(766 bp core region and 55 bp upstream and downstream
regions: 876 bp total) confirmed that the seven plasmid-
borne CTX-m genes were 100% identical to CTX-m-15
reported in GenBank.
Ninety-eight percent (64/65) of the total isolates also
carried the SHV core gene chromosomally. Of note, the
remaining single isolate (01–007967, Table 1) was nega-
tive for the three studied genetic markers. Seventeen
percent (11/65) of isolates carried SHV on the plasmid.
Table 3 Antibiotic resistance profile
Panel of antibiotic tested





































1 (1.5) 32 (49) 64 (98) 9 (14) 65 (100)
The table is divided into three major categories to show the number and percent [N (%) ] of cases with ESBL phenotype by Disc diffusion*, double disc synergy test (for ESBL confirmation)† and E test results ‡ to SXT
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SHV genes on a plasmid, while no plasmid carriage was
detected in the remaining seven isolates.
DNA sequencing analysis of whole SHV gene from 11
isolates revealed 99% similarity to SHV-12. On the
nucleotide level, no similarity was found between the
eleven SHV gene sequences to each other or published
SHV sequences: SHV-12 (GenBank# GU064393.1), and
the closely related SHV-5 (GenBank# HM125696.1), and
SHV-2a (GenBank# GQ407116.1). Comparison of the
corresponding amino acid sequence of each gene utiliz-
ing Lahey organization study tables, demonstrated SHV-
12, SHV-5 and SHV-2a as the most closely related
sequencing match (Table 2). Also, see Additional file 1
PDF displays SHV amino acid sequence variations of
ESBL Egyptian isolates table.
Macro-restriction pattern typing using Pulsed-Field Gel
Electrophoresis (PFGE)
DNA fingerprint profiling of the 65 isolates identified
four major clusters (Figure 1), with strains grouped in
each cluster sharing high levels of similarity (80-100%).
PFGE identified four major clusters: cluster one grouped
32% of the samples (n=21) with 54.5% similarity. Five
of the eleven (45%) plasmid-borne SHV were identified
in this cluster, and their mrp were indistinguishable.
Remarkably, one isolate (01–007967) did not carry any
of the genes, displayed identical MRP to two isolates
(01–007961, and 01–008884) carrying both TEM and
SHV. Cluster two grouped the majority 41.5% of the
isolates (n= 27), sharing 75.6% similarity and forming a
broad cluster. Two plasmid-borne SHV and another two
CTX-m carrying isolates were identified in this cluster and
located distantly from each other. The third cluster is
composed of 19% of the samples (n=12), members of this
cluster did not share identical MRP pattern. The fourth
cluster represented the fewer number of samples 8% (n=5)
where one isolate (03–021322) carried the three genetic
markers for resistance.
PFGE analysis of the seven K. pneumoniae strains
producing CTX-m-15 (Figure 2), using complete linkage,
dice band-based similarity coefficient and 1.5% position
tolerance, revealed 5 clusters: one pair of isolates (pattern
1) was collected from nosocomial infections at a hospital
in Cairo in 2001 (01–015469 and 01–015470; >85% simi-
larity). Another pair (pattern 4) were isolated in Kafr El
Shiek governorate from community-acquired infections in
2003 (03–021318 and 03–021320, > 80% similarity)
displayed a MRP (pattern 3) that is distantly related to
another isolate detected at the same hospital (03–021322,
61.9% similarity). Two isolates each with unique pattern;
one was isolated from Mansoura governorate (nosocomial,
02–005285) formed pattern 4), and another isolate from
Alexandria governorate (community, 03–018785) formedpattern 5. Five distinct DNA fingerprint patterns were
detected with the positive plasmid SHV isolates (Figure 2b).
Interestingly, pattern 1, composed of five isolates (01–
007951, 01–008666, 01–013906, 01–007724, 01–016401),
all were isolated from nosocomial infection collected from
Cairo University. The unique MRP patterns 2 and 4,
displayed by isolates 03–018785, and 03–021322, respect-
ively, were collected from Kafr El-Shiek General Hospital
but was not seen in the seven nosocomial isolates received
from the same location (03–002582). Distinct patterns 3
and 5 came from community isolates collected at Zagazig
University.
Discussion
Antibiograms of K. pneumoniae isolates
Infections caused by ESBLs producing bacteria have become
an emerging global problem. Studies on Enterobacteriaceae
isolates from Egypt have reported a resistance rate to
third generation cephalosporins of 70% [17,18]. A survey,
carried out in 2001–2002 which covered medical centers
in northern and southern European countries, Egypt,
Lebanon, Saudi Arabia and South Africa, reported the
highest incidence of extended spectrum β-lactamases
(ESBLs)-producing isolates in Egypt [3]. A recent study
from Egypt reported an outbreak in a neonatal intensive
care unit in Cairo, Egypt, in which 80% of the isolates
were K. pneumoniae, of which 58% were ESBL producers
[19]. While the phenotypic characteristics of ESBL of
enterobactericeae were widely studied in Egypt, there
were very few published reports on the molecular aspect
underlying mechanism of ESBL. In this study, we investi-
gated the genetic determinants of ESBL activity in K.
pneumoniae isolates collected from 10 different Egyptian
teaching hospitals distributed across seven governorates
in Egypt.
The ESBL activity of K. pneumoniae clinical isolates
collected from both community and hospital settings is
concordant with previous reports from Egypt and other
countries which indicate faecal carriage of these patho-
gens in the community and may have important implica-
tions as a risk factor for acquiring ESBL-producing K.
pneumoniae isolates upon hospital admission. However,
the variable level of resistance of K. pneumoniae to other
non-β-lactam antibiotics, e.g., sulfamethoxazole data, is
not concordant with previous reports from Egypt, where
a high level of resistance was found [20]. The difference
in sulfamethoxazole resistance may be attributed to a wide
dissemination of different ESBL clones of K. pneumoniae
among different community and hospital settings.
Molecular characterization of ESBL genes
CTX-M is the most prevalent gene in ESBL-producing
enterobacteriaceae worldwide [6]. Recently, CTX-M ESBLs
have been reported in different studies in Egypt [10,11,20].
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Figure 1 Phylogenetic tree of Egyptian ESBL isolates (n = 65) demonstrating different clusters by PFGE. C (Chromosomal), and P (Plasmid).
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commonly reported ESBL type in the Middle East and
North Africa [8,20]. In this study, however, the most com-
mon ESBL type identified in Egyptian K. pneumoniae iso-
lates was SHV (98%), compared to the relatively low
prevalence of CTX-m-15 (11%). This differs from a recent
report from Egypt indicating that CTX-M-14 is the mech-
anism of resistance mediating the high resistance of βlactamases K. pneumoniae producers to third generation
Cephalosporins among resistant clinical isolates at a med-
ical institution in Cairo, Egypt [20]. This may indicate that
multiple clones of circulating K. pneumonia are involved in
the dessimination of high ESBL resistance in both commu-
nity and hospital settings. Though this study detected a
relatively small number (11%) of isolates carrying the
CTX-m-15 type of ESBL, it supports our previous report
Isolate number Pattern# CTXM Hospital Location Infection Type
Dice (Opt: 1.50%) (Tol 1.5% - 1.5%) 
(H>0.0% S>0.0%) Xba-1
























Figure 2 PFGE Analysis. 2a. PFGE analysis of the seven CTXM-15 K. pneumoniae producers strains. The dendrogram was constructed with dice
coefficient, complete linkage, and 1.5% position tolerance. The degree of relatedness between K. pneumoniae isolates and those from GenBank is
shown on the branches. 2b. PFGE analysis of the 11 K. pneumoniae strains producing SHV-12, SHV5 and SHV-2a. The dendrogram was
constructed with dice coefficient, complete linkage, and 1.5% position tolerance. The degree of relatedness among K. pneumoniae isolates and
those from GenBank is shown on the branches.
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ESBL-producers in E. coli than in K. pneumoniae [10].
Nevertheless, resistance has been maintained and is sprea-
ding regardless of the use of extended-spectrum cephalo-
sporins in metropolitan areas of Egypt [21]. The evidence
of possible outbreaks involving CTX-m-15 warrants the
implementation of strict hospital infection control policies,including the review of current therapeutic modalities,
control of the use of non-prescribed antibiotics, and con-
tinuous monitoring of antibiotic sensitivity profiles of K.
pneumoniae isolates.
As TEM is the primary genetic element implicated in
the evolution of ESBL resistance mechanisms [22], we
tested for this β-lactamase type. Ninety eight percent
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the chromosome, while only nine percent (6/65) carried
the gene on a plasmid (Table 1). Amplification and DNA
sequencing of the six plasmid-borne genes revealed
100% identity to the TEM-1 gene reported in GenBank
(EU979561.1). Even though TEM 1 is not considered an
extended-spectrum β-lactamase, it may contribute to this
extended spectrum of resistance in concert with other β-
lactamases [4].
It is worth mentioning that isolate 01–007967 did not
carry TEM, SHV, or CTX-M genes either on the chromo-
some or on a plasmid. It is likely that this isolate carries
one or more β-lactamase genes not tested in this study. It
is also possible that any number of the other isolates
carried additional undetected β-lactamase genes that con-
ferred the phenotypic high antimicrobial resistance seen.
Comparison of the corresponding amino acid sequence
of the 11 SHV positive isolates demonstrated the predom-
inance of SHV-12, while SHV-5 and SHV-2a was the most
closely related sequencing match in the remaining isolates.
SHV-12 is thought to have evolved from SHV-2a, and
SHV-5 from SHV-2 [8]. In comparison, SHV-12 contains
only one amino acid (AA) difference at position 31: SHV-
12 possesses a Glutamine, while both SHV-2a and SHV-5
possess a Leucine. Upon blasting the nucleic acid se-
quence of the eleven plasmid-borne SHV genes against
GenBank entries, our collection displayed a matching
similarity value of 99% to SHV-12 and the closely related
SHV-2a and SHV-5 genes [23]. Our phylogenetic tree ana-
lysis illustrated the relatedness among the K. pneumoniae
isolates and SHV-12 (GU064393.1, K. pneumoniae strain
HB 52 β -lactamase blaSHV-12 isolated in Brazil), SHV-2a
(GQ407116.1, K. pneumoniae strain HB 34 β -lactamase
blaSHV-2a isolated in Brazil), and SHV-5 (HM125696.1,
K. pneumoniae strain S-486 β -lactamase SHV-5 isolated
in Russia) GeneBank isolates, enabling to conclude that
these genes are globally circulated.
Among the SHV carrying isolates, polymorphisms
were seen at position 31 (Q or L), position 6 (R or L),
positions 234–235 (SK, GE or SE), and positions 3–4 (YI
or FV) of the enzyme. Of particular interest, four variants
possessed three AA differences at positions 3, 4 and 6
(FV-R versus YI-L). Remarkably, some significant changes
to the functionality of the enzyme were spotted due to
the amino acid substitutions. Occurrence of T17G (Leu
to Arg, position 6 of the enzyme) in four isolates, where
the aliphatic side chain very hydrophobic leucine was
substituted with the basic side chain hydrophilic arginine,
indicates, higher potential in utility modification. Similarly,
the substitutions of the hydroxyl and basic side chain
in serine and lysine with aliphatic and an acidic amide
side chain in glycine and glutamate in three isolates
with different arrangement, suggest functional alteration
at positions 234 and 235 on the enzyme, respectively. Afifth SHV variant (01–013906) possessed these three AA
differences at positions 3, 4 and 6 and an additional two
differences at positions 234 and 235 (GE versus SK).Community vs. nosocomial
Although the number of community isolates was quite
small (7 versus 58) compared to the nosocomial isolates,
a higher ratio of community isolates carried plasmid-
mediated ESBL genes. Fifty seven percent of the commu-
nity isolates carried CTX-m gene versus 5% nosocomial
isolates which had the gene. Moreover, SHV has been
detected in 43% of the community isolates, versus 13%
of the nosocomial isolates. The significant presence of
plasmid-mediated genes among the community isolates
indicates higher potential of exchanging virulence fac-
tors in the community than the relative possibility in
hospitals. In fact, nosocomial outbreaks occur due to
dominating closely related strains that are being trans-
mitted among hospitalized patients within same hos-
pital wards or units. Accordingly, the probability for
wide genetic variations is narrowed in hospital infec-
tions, due to the absence of selective environmental
pressures by specific genetic elements, unlike the case
in community infections where the unconstrained use
of antibiotics is driving the continual transfer of anti-
biotic resistance genes. Thus, suggests applying re-
strictions on antibiotic usage, and the necessity for
advances and finding alternatives for currently available
treatment options.Macro-restriction pattern typing using Pulsed-Field Gel
Electrophoresis (PFGE)
PFGE analysis did not demonstrate an association be-
tween genetic background and any given ESBL pheno-
type. Furthermore, as the macro-restriction pattern of
SHV displays different patterns among the 11 blashv
positive isolates, it suggests possible carriage of the gene
on different antibiotic resistance plasmids [24]. Such a
variety of plasmids gives endless options to exchange
virulence factors like antibiotic resistance, and hence a
high potential of evolution.
In conclusion, this study demonstrates that CTX-m-15,
and SHV-12 genes are associated with an ESBL resistance
phenotype in K. pneumoniae in Egypt, without displaying
a coherent related pattern of a DNA fingerprint profile.
This suggests that the strains are heterogeneous, and their
dissemination, whether in the community or at a hospital,
was driven by strains of different genetic background that
suggests great possibilities of variation and spread. Al-
though one isolate (01–007967) conferred high ESBL
resistance phenotype, it failed to identify any of the three
genes reported in this study. Further investigation is re-
quired to determine the prevalence of such isolates in the
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identify other possible ESBL resistance mechanisms.
It is recommended that future work be done to deter-
mine the plasmid types that carried the plasmid-mediated
genes mentioned, and apply the multilocus sequence
typing (MLST) [13] to characterize the allelic profile of
blaSHV K. pneumoniae isolates circulating in Egypt.
One limitation of the study is that we did not test for
the horizontal movement of genes by performing a
conjugation experiment to examine the self-transferable
capability [25].
Conclusions
This is the first study demonstrated the occurrence of
SHV-12, and SHV-5 and SHV-2a variants in Egypt.
SHV-12 is associated with high-level resistance to
Ceftazidime, and one of the common class A ESBLs
types spreading in K. pneumonia.
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